Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population.
SeaStar Medical also markets a pediatric version of the device, QUELIMMUNE™, for children with AKI and sepsis, which was approved by the FDA earlier this year under a Humanitarian Device Exemption.
Despite the considerable morbidity and mortality associated with acute kidney injury (AKI), over 30 different definitions exist in the published literature. 1 Reasons for the myriad of definitions ...
“The pace of enrollment in our NEUTRALIZE-AKI trial has quickly accelerated, with 14 new subjects enrolled in slightly more than six weeks,” said Kevin Chung, MD, Chief Medical Officer of ...
SeaStar Medical is progressing its pivotal trial evaluating the use of its Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI), with the company announcing that 12 ...
We are thankful for the steady pace of site activations and continued brisk enrollment with our recently activated sites already contributing,” said Kevin Chung, MD, Chief Medical Officer of SeaStar ...
ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports setting a new monthly enrollment record with ...